Investors
Oxurion/Investors/News/Oxurion Discloses Topline Data from KALAHARI Phase 2, Par…

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

20 Nov 2023Regulated information

Documents

English
Download PDF
Nederlands
Download PDF

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.


Back to news